VAXX vs. DARE, EYEN, IMRX, HCWB, NXTC, ACXP, RVPH, NRXP, LPCN, and XLO
Should you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Daré Bioscience (DARE), Eyenovia (EYEN), Immuneering (IMRX), HCW Biologics (HCWB), NextCure (NXTC), Acurx Pharmaceuticals (ACXP), Reviva Pharmaceuticals (RVPH), NRx Pharmaceuticals (NRXP), Lipocine (LPCN), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Vaxxinity (NASDAQ:VAXX) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
Vaxxinity currently has a consensus target price of $7.00, indicating a potential upside of 7,268.42%. Daré Bioscience has a consensus target price of $4.50, indicating a potential upside of 765.38%. Given Vaxxinity's stronger consensus rating and higher possible upside, analysts clearly believe Vaxxinity is more favorable than Daré Bioscience.
83.0% of Vaxxinity shares are owned by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 4.0% of Daré Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Vaxxinity has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
Daré Bioscience received 349 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 73.29% of users gave Daré Bioscience an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Vaxxinity's return on equity of -192.58% beat Daré Bioscience's return on equity.
In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Daré Bioscience'saverage media sentiment score.
Daré Bioscience has higher revenue and earnings than Vaxxinity. Daré Bioscience is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
Summary
Vaxxinity beats Daré Bioscience on 9 of the 15 factors compared between the two stocks.
Get Vaxxinity News Delivered to You Automatically
Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaxxinity Competitors List
Related Companies and Tools
